Top five stories from ESCRS

Clinical research, new technologies and evolving treatments were among the most discussed topics at the 2016 European Society of Cataract and Refractive Surgeons meeting in Copenhagen. New cataract surgery techniques and promising treatments for myopia…

Aerpio Therapeutics Initiates Phase 1a Study of AKB-4924, a First in Class Once-Daily, Orally Administered HIF-1 Stabilizer, in Development to Treat Inflammatory Bowel Disease (IBD)

CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., today announced that it has dosed the first subject in a Phase 1a clinical trial evaluating its product candidate AKB-4924 for the treatment of IBD. This novel, orally administered agent that stabilizes hypoxia inducible factor 1 alpha (HIF-1α), a cellular protein which plays a crucial role in the resolution of inflammation and maintenance of epithelial barrier integrity. In multiple in vivo preclinical models of IBD, AKB-4924 has been sho


Publication Exclusive: Intrastromal corneal ring segment helps correct high astigmatism after DALK

Corneal transplantation has progressed significantly from full-thickness penetrating keratoplasty to selective corneal transplantation in which only the diseased portions of corneal tissue are replaced surgically with similar healthy donor tissue. This has revolutionized corneal transplantation because the healthy parts of the patient’s cornea are retained. When the endothelium is untouched surgically, this eliminates the possibility of endothelial graft rejection. The diseased portion of the cornea needs to be localized to the anterior regions of the patient’s cornea, such as in keratoconus, while the endothelium remains healthy.When the corneal stroma is (Read more...)